Sabutoclax

Catalog No.S8061 Batch:S806104

Print

Technical Data

Formula

C42H40N2O8
Molecular Weight 700.78 CAS No. 1228108-65-3
Solubility (25°C)* In vitro DMSO 100 mg/mL (142.69 mM)
Ethanol 25 mg/mL (35.67 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% corn oil
0.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)		 Bcl-xL [1]
(Cell-free assay)		 Bcl-2 [1]
(Cell-free assay)		 Bfl-1 [1]
(Cell-free assay)
0.20 μM 0.31 μM 0.32 μM 0.62 μM
In vitro

BI-97C1 potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively, and shows little cytotoxicity against bax-/-bak-/- cells[1]. It is suggest that treatment with the combination regimen of mda-7/IL-24 and BI-97C1 induces autophagy that facilitates apoptosis in association with up-regulation of NOXA, accumulation of Bim, and activation of Bax and Bak[2].
In vivo

BI-97C1 displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells and also demonstrates superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model that depends on Mcl-1 for survival[1]. Treatment with Ad.5/3-mda-7 and BI-97C1 significantly inhibits the growth of human PC xenografts in nude mice and spontaneously induced PC in Hi-myc transgenic mice. Tumor growth inhibition correlats with increased TUNEL staining and decreased Ki-67 expression in both PC xenografts and prostates of Hi-myc mice[2].

Protocol (from reference)

Kinase Assay:

[1]
  • Competitive fluorescence polarization assays (FPA)

    For competitive binding assays, 100 nM GST-Bcl-XL ΔTM protein is preincubated with the tested compound at varying concentrations in 47.5 μL PBS (pH = 7.4) in 96-well black plates at room temperature for 10 min, and then 2.5 μL of 100 nM FITC-labeled Bak BH3 peptide is added to produce a final volume of 50 μL. The wild-type and mutant Bak BH3 peptides are included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units are measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader. IC50 is determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model. Data reported are mean of three independent experiments. Performance of Bcl-2 and Mcl-1FPA are similar. Briefly, 50 nM of GST-Bcl-2 or -Mcl-1are incubatedwith various concentrations of compound (4 and 11-14) for 2 min, and then 15 nM FITC-conjugated-Bim BH3 peptide is added in PBS buffer. Fluorescence polarization is measured after 10 min.
Cell Assay:

[1]
  • Cell lines

    PC3, H460, H1299

  • Concentrations

    ~1 μM

  • Incubation Time

    72 h

  • Method

    ATP-LITE assay
Animal Study:

[1]
  • Animal Models

    Bcl-2 transgenic mice, human prostate cancer xenografts

  • Dosages

    1 mg/kg, 3 mg/kg, 5 mg/kg

  • Administration

    intraperitoneally

Customer Product Validation

Data from [Data independently produced by , , Cell Death Differ, 2016, 23(10):1681-90.]

Data from [Data independently produced by , , Cancer Lett, 2018, 423:47-59]

Selleck's Sabutoclax has been cited by 11 publications

Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy [ Cells, 2023, 12(18)2247] PubMed: 37759469
Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy [ Cells, 2023, 10.3390/cells12182247] PubMed: 37759469
Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1 [ Mol Divers, 2022, 10.1007/s11030-022-10494-6] PubMed: 35909144
Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets. [ Platelets, 2020, 10.1080/09537104.2020.1724276] PubMed: 32079453
Alveolar Macrophage Apoptosis-associated Bacterial Killing Helps Prevent Murine Pneumonia. [ Am J Respir Crit Care Med, 2019, 200(1):84-97] PubMed: 30649895
Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia [De Dominici M, et al. Cancer Res, 2018, 78(4):1097-1109] PubMed: 29233926
Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer [Hu Y, et al. Cancer Lett, 2018, 423:47-59] PubMed: 29496539
PPARγ is critical forMycobacterium tuberculosisinduction of Mcl-1 and limitation of human macrophage apoptosis [ PLoS pathogens, 2018, 14(6): e1007100.] PubMed: None
PPARγ is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis. [ PLoS Pathog, 2018, 14(6):e1007100] PubMed: 29928066
PTBP1 modulation of MCL1 expression regulates cellular apoptosis induced by antitubulin chemotherapeutics [Cui J, et al. Cell Death Differ, 2016, 23(10):1681-90] PubMed: 27367564

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.